414. Deputy John Clendennen asked the Minister for Health for an update on the reimbursement of belzutifan, for the treatment of von Hippel-Lindau (VHL) disease, by the HSE; whether the application is being assessed on the most up to date information on the performance of the drug and subsequent patient outcomes; and when a final decision is likely. [66250/26]

Summary

414. Deputy John Clendennen asked the Minister for Health for an update on the reimbursement of belzutifan, for the treatment of von Hippel-Lindau (VHL) disease, by the HSE; whether the application is being assessed on the most up to date information on the performance of the drug and subsequent patient outcomes; and when a final decision is likely. [66250/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 17 September 2026

   Medicinal Products

   414. Deputy John Clendennen asked the Minister for Health for an update on the reimbursement of belzutifan, for the treatment of von Hippel-Lindau (VHL) disease, by the HSE; whether the application is being assessed on the most up to date information on the performance of the drug and subsequent patient outcomes; and when a final decision is likely. [66250/26]

   Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 17 September 2026

  ViewDownloadOpen at official source

Sponsors

• John Clendennen · Asking member
• Health · Health · Addressed to

Related records

No cross-record relationships stored yet.